<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">02008</article-id><article-id pub-id-type="doi">10.7554/eLife.02008</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>APOBEC3A deaminates transiently exposed single-strand DNA during LINE-1 retrotransposition</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-9929"><name><surname>Richardson</surname><given-names>Sandra R</given-names></name><aff><addr-line><named-content content-type="department">Department of Human Genetics</named-content></addr-line>, <institution>University of Michigan Medical School</institution>, <addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-9930"><name><surname>Narvaiza</surname><given-names>Iñigo</given-names></name><aff><addr-line><named-content content-type="department">Laboratory of Genetics</named-content></addr-line>, <institution>The Salk Institute for Biological Studies</institution>, <addr-line><named-content content-type="city">La Jolla</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-9931"><name><surname>Planegger</surname><given-names>Randy A</given-names></name><aff><addr-line><named-content content-type="department">Department of Human Genetics</named-content></addr-line>, <institution>University of Michigan Medical School</institution>, <addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-9932"><name><surname>Weitzman</surname><given-names>Matthew D</given-names></name><aff><addr-line><named-content content-type="department">Department of Pathology and Laboratory Medicine</named-content></addr-line>, <institution>University of Pennsylvania Perelman School of Medicine and the Children's Hospital of Philadelphia</institution>, <addr-line><named-content content-type="city">Philadelphia</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-8792"><name><surname>Moran</surname><given-names>John V</given-names></name><aff><addr-line><named-content content-type="department">Department of Human Genetics</named-content></addr-line>, <institution>University of Michigan Medical School</institution>, <addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line>, <country>United States</country><email>moranj@umich.edu</email></aff><xref ref-type="fn" rid="conf2"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1083"><name><surname>Ferguson-Smith</surname><given-names>Anne</given-names></name><role>Reviewing editor</role><aff><institution>University of Cambridge</institution>, <country>United Kingdom</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>24</day><month>04</month><year>2014</year></pub-date><volume>3</volume><elocation-id>e02008</elocation-id><supplementary-material><ext-link xlink:href="elife-02008-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>05</day><month>12</month><year>2013</year></date><date date-type="accepted"><day>02</day><month>04</month><year>2014</year></date></history><permissions><copyright-statement>Copyright © 2014, Richardson et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Richardson et al</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>Long INterspersed Element-1 (LINE-1 or L1) retrotransposition poses a mutagenic threat to human genomes. Human cells have therefore evolved strategies to regulate L1 retrotransposition. The APOBEC3 (A3) gene family consists of seven enzymes that catalyze deamination of cytidine nucleotides to uridine nucleotides (C-to-U) in single-strand DNA substrates. Among these enzymes, APOBEC3A (A3A) is the most potent inhibitor of L1 retrotransposition in cultured cell assays. However, previous characterization of L1 retrotransposition events generated in the presence of A3A did not yield evidence of deamination. Thus, the molecular mechanism by which A3A inhibits L1 retrotransposition has remained enigmatic.  Here, we have used in vitro and in vivo assays to demonstrate that A3A can inhibit L1 retrotransposition by deaminating transiently exposed single-strand DNA that arises during the process of L1 integration. These data provide a mechanistic explanation of how the A3A cytidine deaminase protein can inhibit L1 retrotransposition.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>John V Moran, is an inventor on patent 6,150,160. Kazazian HH, Boeke JD, Moran JV, Dombroski BA: Compositions and methods of use of mammalian retrotransposons.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></back></article>